Research records indexed for Exenatide
This page carries 12 of the 2,890 records that the literature query returned for Exenatide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 2,878 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Exenatide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial pmid:36066977 | 2022 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Alcoholism; Peptides; Alcohol Drinking; Dopamine Plasma Membrane Transport Proteins; Glucagon-Like Peptide 1. |
| Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial pmid:30640362 | 2019 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Brain; Neurons; Parkinson Disease; Insulin; Mitogen-Activated Protein Kinase 1. |
| Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial pmid:29246950 | 2018 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Venoms; Diabetes Mellitus, Type 2; Body Weight; Metformin; Blood Glucose. |
| Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes pmid:28910237 | 2017 | Comparative Study, research-article | human trial | Not stated | Indexed as comparative study, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Venoms; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Peptides; Hypoglycemic Agents. |
| Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial pmid:28781108 | 2017 | research-article, Randomized Controlled Trial | human trial | Not stated | Indexed as research-article, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Venoms; Parkinson Disease; Peptides; Neurologic Examination; Drug Administration Schedule. |
| Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial pmid:27651331 | 2016 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Venoms; Diabetes Mellitus, Type 2; Metformin; Benzhydryl Compounds; Glucosides. |
| Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy pmid:27106272 | 2016 | Randomized Controlled Trial | human trial | Not stated | Indexed as randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Myocardium; Liver; Pancreas; Heart; Pericardium. |
| Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) pmid:24879836 | 2014 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Venoms; Diabetes Mellitus, Type 2; Hypoglycemia; Metformin; Thiazolidinediones. |
| Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease pmid:24662192 | 2014 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Venoms; Parkinson Disease; Peptides; Antiparkinson Agents; Follow-Up Studies. |
| Exenatide and the treatment of patients with Parkinson's disease pmid:23728174 | 2013 | Research Support, Non-U.S. Gov't, research-article | human trial | Not stated | Indexed as research support, non-u.s. gov't, research-article. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Venoms; Parkinson Disease; Disease Progression; Weight Loss; Constipation. |
| Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study pmid:23141817 | 2013 | Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Not stated | Indexed as research support, non-u.s. gov't, multicenter study. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Venoms; Diabetes Mellitus, Type 2; Peptides; Hypoglycemic Agents; Drug Administration Schedule. |
| Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X) pmid:23698396 | 2013 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Metformin; Peptides; Hypoglycemic Agents; Drug Administration Schedule. |
Where this page sits
Compound page: Exenatide. Class: Incretin receptor agonists.
Retrieved 2026-10-12.
Sources
- PubChem Compound Summary for CID 45588096, Exenatide. PubChem, National Library of Medicine (2026). pubchem:45588096
- Drugs@FDA application register query for this compound, 2 application(s) returned: ANDA206697, NDA021773. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:exenatide
- Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. The Journal of biological chemistry (1992). pmid:1313797
- Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. The Journal of biological chemistry (1993). pmid:8396143
- Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999). pmid:10580413
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes care (2004). pmid:15504997
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes care (2005). pmid:15855571
- Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes care (2005). pmid:15855572
- Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of internal medicine (2005). pmid:16230722
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (London, England) (2008). pmid:18782641
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009). pmid:19515413
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine (2017). pmid:28910237
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet (London, England) (2017). pmid:28781108
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.